Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood

Using advanced epidemiological methods, Programme Area 2 investigates biological, psychosocial and health care-related factors that influence the course and outcome of rheumatic diseases in adults and children. Our research mainly builds on long-term observational studies, conducted in close cooperation with a nationwide network of more than 500 paediatric and adult rheumatology specialists. In addition, specific population-based analyses are carried out using data from health insurance companies ...

Since 2007, the JuMBO registry examines the long-term effects of new rheumatological therapies in patients who developed juvenile idiopathic arthritis (JIA) in childhood. This registry is a subsequent database to the BiKeR registry (headed by Prof. Dr. Horneff of St. Augustin), and its function is to monitor the health of adults post-pediatric rheumatology treatment.The present study focuses on the safety and efficacy of new disease-modifying antirheumatic drugs (DMARDs) and the long-term prognosis ...